|  | | | | | | | | A mass COVID-19 testing order in Beijing's biggest district prompted residents in the Chinese capital to stock up on groceries, fearing they could be destined for a lockdown similar to that of Shanghai. | | | | | | Colombia will lift a face mask mandate for some indoor spaces from May 1, President Ivan Duque said on Monday, though coverings will still be required on transport and in medical facilities and schools. | | | | | | The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc's drug remdesivir. | | | | | | A mandatory housing order for poultry and captive birds in Britain is to be lifted, effective May 2, with the threat of bird flu now decreasing after the country's worst-ever outbreak. | | | | | | Beijing will expand its mass COVID-19 testing campaign to another 10 districts and one economic development area from Tuesday to Saturday, an official for the Chinese capital said late on Monday. | | | | | | Roche has warned that Russia's attack on Ukraine is disrupting the development of a new generation of multiple sclerosis (MS) drugs as the industry has come to disproportionately rely on Eastern Europe for clinical trials. | | | | | | French drugmaker Valneva said on Monday that the European Medicines Agency (EMA) had asked for more data on its COVID-19 vaccine, precipitating a sharp fall in its shares. | | | | | | Here's what you need to know about the pandemic right now: | | | | | | Walgreens Boots Alliance and Teva Pharmaceutical Industries Ltd ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on Monday during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines. | | | | | | Axsome Therapeutics said on Monday it expects the U.S. health regulator to decline approval for its treatment of acute migraine over unresolved issues of its quality control processes, sending shares of the drug developer down 20%. | | | | | | | | | | | | | | | Sponsors are not involved in the creation of these or any other Reuters news articles.
Get Reuters News App
To manage which newsletters you're subscribed to, click here.
Want to stop receiving this email? Unsubscribe here.
To contact us with feedback, reply to this email. | | | | | | | | | |
